AXXAM

In-vitro Assays

Photo of Lysosomes in HTS

Bringing lysosomal patch clamp recording to HTS

Science Spyglass High throughput organellar electrophysiology of TMEM175 and TPC2 from freshly isolated lysosomes recorded on the SyncroPatch 384 Application note Axxam S.p.A., MilanNanion Technologies GmbH, Munich Summary Intracellular ion channels are known to play an essential role in various signaling pathways for health and disease, considering that over 80% of transport processes occur inside […]

Bringing lysosomal patch clamp recording to HTS Read More »

The dualism of the aging and disease

Science Spyglass Navigating the dualism of the aging and disease landscape with the pertinent tools An interview with Fernanda Ricci, High Content Screening Unit Manager at Axxam. Don’t miss her upcoming webinar: Forever young?Targeting the hallmarks of aging 21 February 2024, 16.00 CET Click to register Read Fernanda’s opinions on the subject of early drug

The dualism of the aging and disease Read More »

Solute carrier transporters as therapeutic targets

Science Spyglass Solute carrier transporters and drug discovery: unlocking the “gatekeepers” as therapeutic targets Solute carrier (SLC) transporters comprise a family of more than 450 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes. They play a fundamental role in controlling the transport of molecules, such as ions and

Solute carrier transporters as therapeutic targets Read More »

Thermal shift assays for early-stage drug discovery

Science Spyglass Unlocking the Power of Thermal Shift Assays for Early-Stage Drug Discovery Thermal-shift assay (TSA) represents a powerful tool for protein-stability analysis and for discovering and characterizing new protein binders. Understanding protein stability is crucial for drug development, protein engineering, and other biotechnology applications. Among the various methods available for assessing protein stability, TSA

Thermal shift assays for early-stage drug discovery Read More »

shRNA for gene knock down in screening campaigns

Science Spyglass Why is shRNA better than siRNA for gene knock down in screening campaigns? One of the first challenges to face in the drug discovery process, is the generation of reliable in-vitro models that mimic the pathological conditions of the disease being studied. Many diseases are caused by the loss of function of a

shRNA for gene knock down in screening campaigns Read More »

Scroll to Top